Frank L. Karbe's most recent trade in Cidara Therapeutics Inc was a trade of 115,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 7, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cidara Therapeutics Inc | Frank L. Karbe | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 115,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Frank L. Karbe | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Jan 2026 | 43,125 | 0 (0%) | 0% | - | Common Stock | |
| Cidara Therapeutics Inc | Frank L. Karbe | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 221.50 per share. | 07 Jan 2026 | 7,526 | 43,125 (0%) | 0% | 221.5 | 1,667,009 | Common Stock |
| Cidara Therapeutics Inc | Frank L. Karbe | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 219.60 per share. | 10 Dec 2025 | 7,290 | 50,562 (0%) | 0% | 219.6 | 1,600,884 | Common Stock |
| Phathom Pharma Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharma Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 10,500 | 67,500 (0%) | 0% | 0 | Common Stock | |
| Cidara Therapeutics Inc | Frank L. Karbe | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 115,000 | 115,000 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Frank L. Karbe | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 57,500 | 57,500 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharma Inc | Frank L. Karbe | Director | Purchase of securities on an exchange or from another person at price $ 7.93 per share. | 13 Dec 2024 | 12,500 | 57,000 (0%) | 0% | 7.9 | 99,084 | Common Stock |
| Phathom Pharma Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 10.16 per share. | 29 May 2024 | 25,000 | 44,500 (0%) | 0% | 10.2 | 254,113 | Common Stock |
| Phathom Pharma Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharma Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 10,500 | 19,500 (0%) | 0% | 0 | Common Stock | |
| Better Therapeutics Inc | Frank Karbe L. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 62,500 | 526,516 | - | 0 | Common Stock | |
| Better Therapeutics Inc | Frank L. Karbe | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.73 per share. | 27 Jul 2023 | 137,005 | 429,429 | - | 0.7 | 100,000 | Common Stock |
| Phathom Pharma Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharma Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 9,000 | 9,000 (0%) | 0% | 0 | Common Stock | |
| Better Therapeutics Inc | Frank L. Karbe | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 0.83 per share. | 10 Apr 2023 | 242,424 | 292,424 | - | 0.8 | 200,000 | Common Stock |
| Better Therapeutics Inc | Frank L. Karbe | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 2.09 per share. | 15 Sep 2022 | 50,000 | 50,000 | - | 2.1 | 104,695 | Common Stock |
| Better Therapeutics Inc | Frank L. Karbe | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2022 | 472,200 | 472,200 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharma Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharma Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |